This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME Events News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Journals
    Journal
    05/07/18

    Levosimendan in pulmonary hypertension and right heart failure

    Pulmonary hypertension is a multifactorial disease with a high morbidity and mortality.

    • Source: Pulmonary Circulation
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    13/02/13

    Bayer files riociguat for CTEPH and Pulmonary Arterial Hypertension at FDA and EU

    Bayer HealthCare has submitted the oral investigational drug riociguat to treat patients with inoperable Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    09/10/13

    Adempas (Bayer) is FDA approved for Pulmonary Hypertension and CTEPH

    The FDA has on 8 October 2013 approved Adempas (riociguat) from Bayer HealthCare to treat adults with two forms of...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    16/03/19

    Interim analysis of REPAIR study of Opsumit shows improved heart function in pulmonary arterial hypertension

    Actelion Pharmaceuticals announced an interim analysis from the Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension (REPAIR) study of Opsumit (macitentan)...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    29/06/23

    MAA submitted to the European Medicines Agency for approval of single tablet combination therapy of macitentan and tadalafil for treatment of pulmonary arterial hypertension

    The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of a single tablet combination therapy of macitentan 10 mg and tadalafil 40 mg (M/T STCT) for the long-term treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) in adult patients of WHO functional class (FC) II-III

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    08/04/22

    Long-term BREEZE safety study of Tyvaso DPI in pulmonary arterial hypertension

    Long-term BREEZE safety study of Tyvaso DPI in pulmonary arterial hypertension published in Pulmonary Circulation journal.- United Therapeutics United Therapeutics announced the publication of additional clinical and long-term safety data from the BREEZE study evaluating Tyvaso DPI (treprostinil) in patients with pulmonary arterial hypertension (PAH) in the journal Pulmonary Circulation.

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    08/02/22

    Opsynvi becomes the first and only Health Canada-approved once daily, fixed dose, combination treatment for pulmonary arterial hypertension. -Janssen Pharmaceuticals.

    The Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada approved Opsynvi (macitentan 10mg and tadalafil 40mg) for the long-term treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to reduce morbidity in patients of WHO functional class (FC) II or III whose PAH is idiopathic, heritable, or associated with connective tissue disease or congenital heart disease.

    Journals
    Journal
    30/09/18

    Ambulatory Intravenous Inotropic Support and or Levosimendan in Pediatric and Congenital Heart Failure: Safety, Survival, Improvement, or Transplantation

    End-stage heart failure (HF) frequently needs continuous inotropic support in hospital and has high morbidity and mortality in absence of heart transplantation.

    • Source: Pediatric Cardiology
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    20/06/16

    INOpulse delivery system enters phase III trial to treat Pulmonary Arterial Hypertension.- Bellerophon Therapeutics.

    Bellerophon Therapeutics, Inc.announced that the first subject has been enrolled in the Phase III INOvation-1 clinical trial. The first patient...

    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    13/03/23

    Phase III A DUE data show single tablet combination therapy of macitentan and tadalafil significantly improves pulmonary hemodynamics versus monotherapy in pulmonary arterial hypertension - Janssen Pharmaceuticals

    The Janssen Pharmaceutical Companies of Johnson & Johnson announced results from the Phase III A DUE study (NCT03904693), which showed an investigational once-daily, single tablet combination therapy, also known as fixed dose combination, of macitentan 10 mg and tadalafil 40 mg (M/T STCT), significantly improved pulmonary hemodynamics (blood flow through pulmonary blood vessels) versus macitentan and tadalafil monotherapies in pulmonary arterial hypertension (PAH) patients with World Health Organization (WHO) functional class (FC) II or III.[1] The data were presented as a Late-Breaking Clinical Trial presentation during the American College of Cardiology’s 72nd Annual Scientific Session & Expo Together With World Heart Federation’s World Congress of Cardiology.

    See more